Home › Companies › Rhythm Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Rhythm Pharmaceuticals, Inc.’s Form 8-K, filed June 25, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 24, 2026: 4 items on Rhythm Pharmaceuticals, Inc.’s Form 8-K, filed June 25, 2026: 1 approved · 3 passed (calculated).
Notable dissent: 1 director (14.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13F, 9.6%, as of September 30, 2026)
Explore Rhythm Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Rhythm Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 25, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David W. J. McGirr | 53,167,971 | -- | -- | 8,704,527 | 2,273,648 | 86% | Passed (calculated) | — |
| Elect Director: David P. Meeker, MD | 59,961,848 | -- | -- | 1,910,650 | 2,273,648 | 97% | Passed (calculated) | — |
| 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 | 63,924,852 | 197,701 | 23,593 | -- | 0 | 99.7% | Passed (calculated) | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 50,368,659 | 11,467,157 | 36,682 | -- | 2,273,648 | 81% | Approved | — |
Source: Rhythm Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 25, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
318 asset managers disclosed a vote on at least one Rhythm Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David P. Meeker, M.D.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Meeker, MD”): 59,961,848 for, 1,910,650 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 26,706,633 for, 457,133 withheld, 17,581 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,341 | 0 | 4 | 3,459 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,793 | 0 | 0 | 10 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 0 | 0 | 0 | 415,259 | Withhold |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 124,948 | 0 | 0 | 3,294 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of the Class III directors, each to serve for a three year term until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: David W.J. McGirr
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David W. J. McGirr”): 53,167,971 for, 8,704,527 withheld, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 24,455,090 for, 2,025,206 withheld, 701,050 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,298,324 | 0 | 21 | 3,459 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,053,968 | 0 | 0 | 8,835 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 0 | 437,490 | 0 | Abstain |
| Putnam | 0 | 0 | 0 | 415,259 | Withhold |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 283,662 | Withhold |
| Legg Mason | 275,593 | 0 | 0 | 4,112 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 203,950 | 0 | 26,095 | 0 | Mixed |
| Lord Abbett | 0 | 0 | 0 | 226,824 | Withhold |
| Equitable | 79,391 | 0 | 0 | 128,685 | Mixed |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 196,524 | Withhold |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 152,881 | Withhold |
| Bridge Builder Trust | 44,584 | 0 | 96,950 | 0 | Mixed |
| Goldman Sachs | 113,058 | 0 | 0 | 15,184 | Mixed |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Combines 10 wordings of this item as funds reported it.
81% Approved · of votes cast
Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 50,368,659 for, 11,467,157 against — passed, per its Form 8-K filed June 25, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”
Support: 81% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,301,781 | 23 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 0 | 1,626,217 | 0 | 0 | Against |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,053,968 | 8,835 | 0 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 0 | 437,490 | 0 | 0 | Against |
| Putnam | 0 | 415,259 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 294,669 | 0 | 0 | Against |
| Invesco | 0 | 289,357 | 0 | 0 | Against |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 275,593 | 4,112 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 44,584 | 96,950 | 0 | 0 | Mixed |
| Goldman Sachs | 113,058 | 15,184 | 0 | 0 | Mixed |
Fund voting reports, all 84 managers: 23,202,800 for, 3,959,834 against, 18,712 abstained, 79 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 6,616,427 | 0 | 0 | 0 | For |
| BAKER BROS. ADVISORS LP | 5,604,483 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 3,406,249 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 0 | 3,055,872 | 0 | 0 | Against |
| BlackRock | 2,718,872 | 8,500 | 119 | 0 | For |
| State Street | 2,137,197 | 23,382 | 0 | 0 | For |
| T. Rowe Price | 1,881,923 | 0 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 0 | 1,750,593 | 0 | 0 | Against |
| Fidelity | 1,614,643 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,505,179 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,412,746 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 0 | 1,410,524 | 0 | 0 | Against |
| Janus Henderson | 1,276,610 | 14,502 | 0 | 0 | For |
| Federated Hermes | 1,281,535 | 0 | 0 | 0 | For |
| Checkpoint Capital L.P. | 1,187,666 | 0 | 0 | 0 | For |
| Siren, L.L.C. | 1,136,275 | 0 | 0 | 0 | For |
| AllianceBernstein | 899,340 | 0 | 0 | 0 | For |
| Citadel | 881,582 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0 | 655,644 | 0 | 0 | Against |
| Clearbridge Investments, LLC | 653,918 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 0 | 650,814 | 0 | 0 | Against |
| Putnam | 0 | 575,431 | 0 | 0 | Against |
| Charles Schwab | 532,245 | 0 | 0 | 0 | For |
| Vanguard | 512,767 | 1,896 | 0 | 0 | For |
| Woodline Partners LP | 482,080 | 0 | 0 | 0 | For |
Institutional-manager reports, all 261 managers: 39,319,852 for, 12,187,275 against, 4,046 abstained, 35,489 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.7% Majority: yes · of votes cast
Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Rhythm Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 63,924,852 for, 197,701 against, per its Form 8-K filed June 25, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 84 asset managers below reported 27,162,603 for, 31 against, 18,712 abstained, 79 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,301,804 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 3,218,761 | 0 | 0 | 0 | For |
| BlackRock | 3,056,515 | 0 | 0 | 0 | For |
| Fidelity | 2,582,329 | 0 | 0 | 0 | For |
| Capital Group | 1,626,217 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,271,178 | 0 | 0 | 0 | For |
| Federated Hermes | 1,239,612 | 0 | 0 | 0 | For |
| State Street | 1,062,772 | 31 | 0 | 0 | For |
| JPMorgan | 1,051,685 | 0 | 0 | 0 | For |
| Charles Schwab | 527,140 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 437,490 | 0 | 0 | 0 | For |
| Putnam | 415,259 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 294,669 | 0 | 0 | 0 | For |
| Invesco | 289,357 | 0 | 0 | 0 | For |
| AllianceBernstein | 283,662 | 0 | 0 | 0 | For |
| Legg Mason | 279,705 | 0 | 0 | 0 | For |
| Loomis Sayles | 253,415 | 0 | 0 | 0 | For |
| Jackson National | 230,045 | 0 | 0 | 0 | For |
| Lord Abbett | 226,824 | 0 | 0 | 0 | For |
| Equitable | 208,076 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 196,524 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 160,640 | 0 | 0 | 0 | For |
| Voya | 152,881 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 141,534 | 0 | 0 | 0 | For |
| Goldman Sachs | 128,242 | 0 | 0 | 0 | For |
Showing the 25 largest of 84 asset managers. All 84 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 68,445,084 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.21% |
| 2 | PRIMECAP Odyssey Funds | 4.70% |
| 3 | BlackRock | 4.47% |
| 4 | Fidelity | 3.77% |
| 5 | Capital Group | 2.38% |
| 6 | T. Rowe Price | 1.86% |
| 7 | Federated Hermes | 1.81% |
| 8 | State Street | 1.55% |
| 9 | JPMorgan | 1.54% |
| 10 | Charles Schwab | 0.77% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 9.67% |
| 2 | BAKER BROS. ADVISORS LP | 8.19% |
| 3 | PRIMECAP MANAGEMENT CO/CA/ | 4.98% |
| 4 | Polar Capital Holdings Plc | 4.46% |
| 5 | BlackRock | 3.98% |
| 6 | State Street | 3.16% |
| 7 | T. Rowe Price | 2.75% |
| 8 | WESTFIELD CAPITAL MANAGEMENT CO LP | 2.56% |
| 9 | Fidelity | 2.36% |
| 10 | PERCEPTIVE ADVISORS LLC | 2.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| RA Capital Management, L.P. | 6,666,837 | 9.74% | Schedule 13G, filed February 17, 2026 |
| BlackRock | 6,237,151 | 9.11% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 6,210,916 | 9.07% | Form 13F, quarter ended March 31, 2026 |
| PRIMECAP MANAGEMENT CO/CA/ | 3,478,669 | 5.08% | Schedule 13G, filed February 12, 2026 |
| State Street | 2,271,851 | 3.32% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 1,965,432 | 2.87% | Form 13F, quarter ended March 31, 2026 |
| FMR (Fidelity) | 1,689,671 | 2.47% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 1,654,876 | 2.42% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 1,553,644 | 2.27% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 1,453,019 | 2.12% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 68,445,084 shares outstanding, as reported by Rhythm Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Rhythm Pharmaceuticals, Inc.'s shareholder meeting held June 24, 2026, in the 2025-2026 proxy season, 318 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,682 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — Rhythm Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 81% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Rhythm Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 25, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rhythm Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Rhythm Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Rhythm Pharmaceuticals (RYTM) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/rhythm-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.